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Abstract
Background: Prozone means false-negative or false-low results in antigen-antibody reactions, due to an excess of
either antigen or antibody. The present study prospectively assessed its frequency for malaria rapid diagnostic tests
(RDTs) and Plasmodium falciparum samples in an endemic field setting.
Methods: From January to April 2010, blood samples with P. falciparum high parasitaemia (≥ 4% red blood cells
infected) were obtained from patients presenting at the Provincial Hospital of Tete (Mozambique). Samples were
tested undiluted and 10-fold diluted in saline with a panel of RDTs and results were scored for line intensity (no
line visible, faint, weak, medium and strong). Prozone was defined as a sample which showed no visible test line or
a faint or weak test line when tested undiluted, and a visible test line of higher intensity when tested 10-fold
diluted, as observed by two blinded observers and upon duplicate testing.
Results: A total of 873/7,543 (11.6%) samples showed P. falciparum, 92 (10.5%) had high parasitaemia and 76 were
available for prozone testing. None of the two Pf-pLDH RDTs, but all six HRP-2 RDTs showed prozone, at
frequencies between 6.7% and 38.2%. Negative and faint HRP-2 lines accounted for four (3.8%) and 15 (14.4%) of
the 104 prozone results in two RDT brands. For the most affected brand, the proportions of prozone with no
visible or faint HRP-2 lines were 10.9% (CI: 5.34-19.08), 1.2% (CI: 0.55-2.10) and 0.1% (CI: 0.06-0.24) among samples
with high parasitaemia, all positive samples and all submitted samples respectively. Prozone occurred mainly, but
not exclusively, among young children.
Conclusion: Prozone occurs at different frequency and intensity in HRP-2 RDTs and may decrease diagnostic
accuracy in the most affected RDTs.
Background
Currently malaria rapid diagnostic tests (RDTs) detect
Plasmodium antigens in blood by antibody-antigen
interactions on a nitrocellulose test strip. The targeted
antigens include those specific to Plasmodium
falciparum (histidine-rich protein-2 (HRP-2) and
P. falciparum-specific parasite lactate dehydrogenase
(Pf-pLDH)) and antigens common to P. falciparum,
Plasmodium vivax, Plasmodium ovale and Plasmodium
malariae (pan-species pLDH and aldolase). RDTs com-
bine a control line with one, two or three antigen-
detecting test lines, and are referred to as two-, three-
and four-band RDTs respectively.
RDTs are being rolled out as an alternative to micro-
scopic diagnosis in malaria endemic settings [1] and
have demonstrated sensitivities close to 100% for the
detection of P. falciparum at densities above 100 asexual
parasites/μl or > 0.002% of parasitized red blood cells
(RBC). Most false-negative results occur at lower para-
site densities. However, false-negative results have been
reported also at high parasite densities. Part of those
m a yb ea s c r i b e dt og e n e t i cv a r i a t i o n so ft h eH R P - 2
[2-6], but the prozone phenomenon may also be
involved. Prozone is defined as false-negative or false-
low results in antigen-antibody immunological reactions,
d u et oa ne x c e s so fe i t h e ra n t i g e n so ra n t i b o d i e s[ 7 , 8 ] .
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with high P. falciparum parasite densities and dilution
of the sample can trace and correct the effect [9]. In a
recent laboratory evaluation, RDT brands were chal-
lenged to a panel of clinical samples with P. falciparum.
Prozone was observed among 16 out of 17 HRP-2 RDTs
but not among five Pf-pLDH RDTs [9]. However, as this
was a retrospective laboratory study in a reference set-
ting, the frequency and impact of the prozone effect on
the diagnosis of malaria in the daily practice of endemic
settings remains to be determined.
The main aim of the present study was to assess the
f r e q u e n c yo ft h ep r o z o n ee f f e c ti nam a l a r i ae n d e m i c
field setting. A subsidiary aim was the confirmation of
the previous observation that HRP-2 RDTs, but not Pf-
pLDH tests, are affected by prozone [9].
Methods
Study site, study period and patients included
The study was conducted in the emergency ward of the
Provincial Hospital of Tete (PHT), located in Central
Mozambique. In this area, malaria is predominantly
caused by P. falciparum. Transmission is perennial with
peaks during and at the end of the rainy season
(February - April)[10,11].
The PHT serves as a reference hospital for Tete
Province (1,700,000 inhabitants). According to hospital
statistics, yearly approximately 50.000 patients present
themselves with clinical suspicion of malaria. Diagnosis
is confirmed in about 20% of them (either by RDT or
microscopy). For this study, all patients suspected of
malaria and presenting at the emergency ward of the
PHT were prospectively included on a 24 hours/7 days
basis from January till April 2010.
Patients, samples and diagnostic work-up
Routine procedures for malaria diagnosis (following
national guidelines) at PHT are as follows: EDTA-antic-
oagulated blood is sampled and a full blood count is
performed by an automated haematology analyzer
(KX-21N, Sysmex, Kobe, Japan). For children ≤ 5 years,
malaria diagnosis is made on a thick blood film (TBF).
For patients above five years of age, an RDT is per-
formed and in case of a positive result a TBF is made
for confirmation and determination of parasite density.
TBFs are stained for 20 minutes at pH 7.2 using Giemsa
3.5% (Merck, KGmA, Darmstadt, Germany). According
to the national malaria clinical guidelines, parasite den-
sity is scored on a semi-quantitative scale from 1+ (1-9
asexual parasites/100 high power microscopic fields) to
5+ (> 100 asexual parasites/1 high power microscopic
field) [12]. During the study period, three RDT brands
(ICT Malaria, Paracheck-Pf and SD Malaria Antigen Pf
FK50) were routinely used (provided by the national
malaria programme or a partner NGO).
For the purpose of the study, demographic data, pre-
senting symptoms and clinical signs of severe malaria
[13] were recorded for all patients with clinical suspicion
of malaria attending the PHT. In addition, TBFs were
performed for all suspected patients, irrespective of their
age. For TBFs positive for P. falciparum and scored as 4
+ or 5+, parasite densities were quantitatively assessed:
the number of asexual parasites was counted against
200 white blood cells (WBC) and converted to para-
sites/μl using the WBC count/μl. Hereafter, values were
converted to % of parasitized RBC using the RBC
count/μl. WBC and RBC counts were those provided by
the haematology analyzer.
Samples with a high parasitaemia, defined as ≥ 4% of
parasitized RBC [14,15], were challenged against a panel
of RDTs consisting of four HRP-2 RDTs and two Pf-
pLDH RDTs (see below and Table 1). Determination of
parasite density and testing of RDTs were done at the
latest 48 hours after sampling and samples were stored
at 4°C pending RDT testing. Analyses were performed
by the regular laboratory staff as well as the authors PG,
AS, JS and HC. Left-overs of the EDTA blood samples
were stored at -20°C till the end of the study for further
analyses.
Malaria rapid diagnostic tests used and test procedures
Malaria RDTs in cassette format were selected based on
demonstrated diagnostic accuracy [16-18], use by
national malaria control programmes and non-govern-
mental organizations (NGOs) and availability in
Mozambique.
For each sample with high parasitaemia, a 10-fold
dilution was made in saline. Both undiluted and diluted
sample were assessed with each RDT brand and tests
were run in duplicate and read by two observers. The
second observer was blinded to the first observer’s read-
ings. Tests were performed according to the instructions
of the manufacturer, except for the use of an automatic
pipette (Finnpipette, Helsinki, Finland) instead of the
RDT kits’ transfer device. Test line intensities were
scored into five categories: none (no line visible), faint
(barely visible), weak (paler than the control line), med-
ium (equal to the control line) and strong (stronger
than the control line) [19]. When a control line did not
appear, the test was interpreted as invalid and the sam-
ple was retested. To assure timely readings, tests were
performed in time-controlled batches. Readings were
carried out at daylight, within the prescribed reading
delay.
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Two additional HRP-2 RDT brands (Hexagon Malaria
Combi and Malaria Pan/Pv/Pf Rapid device), not deliv-
ered in time for the prospective analysis, were assessed
at the end of the study period with samples that had
been stored at -20°C (maximum storage duration: 121
days).
In order to investigate the prozone occurrence at
parasite densities below 4%, all RDT brands were also
assessed with a subset of 45 samples scored as 4+ or 5+
but with parasite densities below 4%.
To confirm the prozone susceptibility of HRP-2 RDTs,
an additional panel of four HRP-2 based RDTs was
assessed with a subset of stored samples that had
demonstrated prozone for at least one of the prospec-
tively assessed HRP-2 RDTs (Table 1). Among the eval-
uated RDTs, there was also an additional lot number of
Malaria Pan/Pv/Pf Rapid Device. The results of these
latter panels were not included for calculation of the
frequency of prozone.
Test outcomes and definitions
Samples with high parasitaemia were defined as samples
with parasite densities ≥ 4%. Prozone was defined if a
sample showed no visible test line or a faint or weak
test line when tested undiluted, and a visible test line of
higher intensity when tested 10-fold diluted, as observed
by two blinded observers and upon duplicate testing [9].
Table 1 Panel of RDT brands used in the study
Brands/manufacturers and Lot numbers Format and Plasmodium antigens targeted
(P. falciparum target is underlined)
WHO FIND
Procurement list *
WHO FIND
Evaluation
†
ICT Malaria ICT Diagnostics, Cape Town, South
Africa
Lot n°: 32784
Two-band: HRP-2 yes yes
Paracheck-Pf Orchid Biomedical Systems, Goa,
India
Lot n°: A31003, 31672, 32972, 31797
Two-band: HRP-2 yes yes
SD Malaria Antigen Pf FK50 Standard
Diagnostics, Hagal-Dong, Korea
Lot n°: 082011, 082012, 080216
Two-band: HRP-2 yes yes
SD Malaria Ag Pf/Pan FK60 Standard
Diagnostics, Hagal-Dong, Korea
Lot n°: 090008, 090010, 090026
Three-band: HRP-2, pan-pLDH yes yes
Hexagon Malaria Combi
‡ Human Wiesbaden,
Germany
Lot n°: 80930
Three-band: HRP-2, aldolase no yes
Malaria Pan/Pv/Pf Rapid Device
‡ Biotec
laboratories Ltd., Ipswitch, UK
Lot n°: 91081, 91100
Four-band: HRP-2, Pan-pLDH, Pv-pLDH no no
CareStart Malaria pLDH Acces Bio, New Jersey,
USA
Lot n°: B191L, A101L
Three-band: Pf-pLDH, pan-pLDH no yes
SD Malaria pLDH FK40 Standard Diagnostics,
Hagal-Dong, Korea
Lot n°: 081006
Three-band: Pf-pLDH, pan-pLDH no yes
First Response Malaria Ag Combo
$
Premier Medical Coorporation Ltd., Daman,
India
Lot n°: 6900309
Three-band: HRP-2, Pan-pLDH yes yes
Hexagon Malaria
$
Human, Wiesbaden, Germany
Lot n°: 0001
Two-band:: HRP-2 no yes
ICT Malaria Combo
$
ICT Diagnostics, Cape Town, South Africa
Lot n°: 32250
Three-band: HRP-2, Aldolase no yes
Malaria Total Quick
$
Cypress Diagnostics, Leuven, Belgium
Lot n°: 090002
Three-band:HRP-2, Pan-PLDH no no
* Included in the interim selection for procurement of malaria rapid diagnostic test [43].
† Evaluated by WHO/FIND [16,17].
‡ RDTs assessed for prozone on stored samples at the end of the study.
$ Additional panel of RDTs assessed at the end of the study with a subset of stored samples positive for prozone for at least one of the prospectively assessed
HRP-2 RDTs.
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total number of samples with high parasitaemia, the
total number of P. falciparum positive samples and the
total number of patients suspected of malaria.
Quality control
At the start of the study, the laboratory staff received a
refresher course on malaria microscopy and RDTs. The
study team was trained on study procedures and flow
during a pilot phase.
All RDTs were purchased in Belgium and shipped to
Tete, except for SD malaria Antigen Pf FK 50 and the
lot A31003 of the Paracheck-Pf which were provided
locally. During shipment and storage, temperature and
humidity were monitored using loggers (Ebro Electronic
GmBH, Ingolstadt, Germany). On a daily basis, 10% of
TBFs were randomly elected and reread by a member of
the study team who was blinded to the original result.
All discordances were resolved by a third reader’sr e a d -
ing. A photograph was taken from all RDT tests per-
formed and the TBFs were stored for quality control.
Data management and statistical analysis
According to the initial sample size calculation, a total
of 5,700 patients suspected of malaria were required for
reliable estimation of the frequency of prozone. This
was based on the following assumptions and informa-
tion from hospital statistics: malaria-attributable fraction
during the wet season of 30%, prevalence of hyperpara-
sitaemia of 10%, prozone frequency among hyperparasi-
taemia samples of 30% with 95% confidence intervals
(CI) between 20% and 40%.
Data were recorded in registers and on individual case
report forms. Data were entered in Microsoft Access
(Microsoft Corporation, Redmond, Washington USA)
and analyzed in Stata 11.1 (StataCorp LP, College Sta-
tion, USA). Differences between proportions were tested
for significance using the Pearson’s Chi-square test or,
in case of small sample sizes, a two-tailed Fisher’s exact
test. Reproducibility and inter-observer reliability for
line intensity readings were assessed using the kappa
statistic for paired observers and percentage agreements.
Differences between medians were tested using the Wil-
coxon test. Lot variations for matched pairs of samples
were assessed using the McNemar’s test. The relation
between line intensities of prozone samples across the
parasite densities was assessed using the Cuzick’st e s t
for trend. A p-value < 0.05 was considered as significant.
Ethical review
The study was approved by the Institutional Review
Board of ITM, by the ethical committee of Antwerp
University, Belgium and by the Comité Nacional de
Bioética para a Saude (MoH), Mozambique. Patients,
children’s parents or guardians were informed in Portu-
guese or in the local language (Nhungue) and their writ-
ten consent was required prior to enrolment.
Results
Patients, samples included and flow chart of the study
During the study period, a total of 7,543 patients with
suspicion of malaria were included, of whom 873
(11.6%) were diagnosed with P. falciparum infection by
thick blood film (Figure 1). About half of the positive
patients with available TBF had parasite densities of 4+
or 5+ (410/861, 47.6%) and 92 had parasite densities ≥
4%. Table 2 summarizes the demographic and parasito-
logical characteristics of malaria positive patients with
complete available data.
Quality assessment, invalid test results, reproducibility
and inter-observer reliability
Shipment and storage temperatures of RDTs ranged
between 4.0°C and 23.5°C (mean 17.5 ± 8.7°C) and 23.3°
C and 32.3°C (mean 28.9 ± 1.5°C) respectively. Storage
temperatures exceeded the highest allowed temperature
(30°C) for three RDT brands Hexagon Malaria Combi,
Malaria Pan/Pv/Pf Rapid Device and CareStart Malaria
pLDH): temperatures of 31°C and 32°C were registered
for a cumulative period of 7.6 and 1 days respectively.
Invalid results were observed for five brands and ranged
between 0.2% and 0.7% of tests performed; upon repeti-
tion all tests performed well. For the HRP-2 line intensity
readings, the overall agreement among the two observers
ranged from 86.1% (Paracheck-Pf) to 97.1% (SD malaria
Ag Pf/Pan FK 60) and kappa values ranged from 0.67
(Malaria Pan/Pv/Pf rapid device) to 0.90 (ICT Malaria).
The reproducibility of the RDTs among the duplicate
tests in terms of HRP-2 line intensity ranged from 71.7%
(Hexagon Malaria Combi) to 97.4% (SD malaria Ag Pf/
Pan FK 60) and kappa values ranged from 0.5 (Hexagon
Malaria Combi) to 0.8 (SD malaria Ag Pf/Pan FK 60).
Frequency of the occurrence of prozone
Prozone affected all six HRP-2 RDT brands in propor-
tions ranging from 6.7% to 38.2% of samples tested. The
two Pf-pLDH RDTs did not show any prozone positive
sample. Table 3 lists for each RDT brand and samples
with high parasitaemia the frequencies for which pro-
zone was observed, matched with the line intensity of
the undiluted sample. Among 104 test results with pro-
zone, negative, faint and weak HRP-2 test lines were
observed in 4 (3.8%), 15 (14.4%) and 85 (81.7%) results.
Two RDT brands accounted for all negative and faint
test lines. The three samples with negative test lines
(including one sample with negative results for two
RDT brands) had parasite densities of 8.3%, 8.3% and
8.4% (Figure 2).
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Patients suspected of malaria 
873 
 
P. falciparum Thick Blood Film 
positive patients 
6,670 
 
Malaria negative patients 
451 
 
1+, 2+ or 3+ 
(MoH semi-quantitative scale) 
410 
 
4+ or 5+ 
(MoH semi-quantitative scale) 
318 
 
Parasite density < 4 % 
92 
 
Parasite density 4 % 
16 
 
EDTA blood samples not 
available  
76 
 
Prozone testing: 
6 HRP-2 and 2 Pf-pLDH RDTs 
29 
 
Prozone (Paracheck-Pf)* 
47 
 
No prozone (Paracheck-Pf)* 
45 
 
Additional samples selected for 
further HRP-2 RDTs testing 
7 
 
Prozone (Paracheck-Pf)* 
 
39 
 
No prozone (Paracheck-Pf)* 
12 
 
TBF not available for scoring of 
parasite density  
Figure 1 Flow of patients and samples. Footnotes figure 1: * Prozone results presented for Paracheck-Pf, results for other RDTs are listed in
Table 3. For definition of prozone see text.
Table 2 Characteristics of P. falciparum samples included
Parasite density (MoH semi-quantitative scale) Age group (nrs)
Children 0 - 5 years Children 5-14 years Adults (≥ 15 years) No data Total
1+ 39 19 97 12 167
2+ 24 18 85 11 138
3+ 27 20 91 8 146
4+ 81 40 110 9 240
5+ 97 32 36 5 170
Total 268 129 419 45 861
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and Pf- pLDH (n = 2) RDT brands.
Brands/manufacturers P. falciparum
antigen targeted
Number of
samples
tested
Total number
of samples with
prozone (%)
HRP-2 or Pf-pLDH line intensity for
undiluted prozone positive samples
Negative Faint Weak
Paracheck-Pf HRP-2 76 29 (38.2) 3 5 21
ICT Malaria HRP-2 76 27 (35.5) 1 10 16
SD Malaria Antigen Pf FK50 HRP-2 76 25 (32.9) - - 25
Hexagon Malaria Combi HRP-2 72 12 (16.7) - - 12
SD Malaria Ag Pf/Pan FK60 HRP-2 76 6 (7.9) - - 6
Malaria Pan/Pv/Pf Rapid
Device
HRP-2 75 5 (6.7) - 5
SD Malaria pLDH FK40 Pf-pLDH 76 - - - -
CareStart Malaria pLDH Pf-pLDH 76 - - - -
Figure 2 Example of prozone for Paracheck-Pf. Footnotes figure 2: Paracheck-Pf RDT cassettes run with a blood sample infected with P.
falciparum at a parasite density of 8.3%. The sample was assessed in duplicate, undiluted (P25 A and P25 B), 10 × diluted (P25 × 10A and P25 ×
10B) and 100 × diluted (P25 × 100A and P25 × 100B). All cassettes show regular control lines, cassettes P25 A and B show no visible test line.
Cassettes P25 × 10A and P25 × 10B show weak test lines and the maximum line intensity (strong) was obtained after 100 × dilution (cassettes
P25 × 100A and P25 × 100B).
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zone for the most affected (in terms of line intensities)
RDT brand (Paracheck-Pf) according to different
denominators. As an example, the proportions of false
negative or faint HRP-2 lines were 10.9%, 1.2% and 0.1%
among the samples with parasite densities ≥ 4%, all P.
falciparum positive samples and all suspected samples
respectively. For the ICT malaria similar proportions
were 14.1% (CI: 7.74-22.95); 1.5% (CI: 0.80-2.53) and
0.2% (CI: 0.09-0.29) respectively.
Table 5 lists the clinical and laboratory data for the
samples with and without prozone for Paracheck-Pf.
Among the high parasitaemia samples, prozone
occurred most frequently but not exclusively among the
group less than five years of age. No significant relation
between prozone and the presenting symptoms was
found. However, cough was significantly more prevalent
among the prozone positive group. Of note, clinical
signs of severity were not associated with prozone, and,
moreover, prozone occurred also in 10 (36%) patients
without any sign of severe malaria. Among the labora-
tory values, the prozone group was significantly asso-
ciated with lower hemoglobin levels and RBC counts.
Parasite densities of prozone positive and prozone nega-
tive samples did not differ significantly.
Table 6 lists the number of HRP-2 based brands
affected by prozone in relation to parasite density as
well as the results for the subset of 45 additional sam-
ples of parasite densities < 4% (mean ± SD parasite den-
sity: 2.7 ± 0.9%). Prozone occurred less frequently in
samples with parasite densities < 4% compared to sam-
ples with high parasitaemia (13/45 versus 39/76, p =
0.016). Prozone occurred dispersedly among the samples
but the intensity of prozone (in terms of numbers of
negative, faint or weak test lines among undiluted sam-
ples) increased with parasite density (p = 0.015). The
three samples with prozone in five out of six HRP-2
RDTs had parasite densities of 8.7%, 11.5% and 28.7%
respectively. Among the samples with parasite densities
< 4%, samples with negative test lines were not observed
a n dp r o z o n ew i t hf a i n tt e s tl i n e sw a so b s e r v e df o ro n l y
one brand (ICT Malaria, at parasite densities of 2.2%,
2.9% and 3.4% respectively).
Table 7 lists the results for the additional HRP-2
RDT brands assessed with samples that were prozone
positive for at least one of the brands assessed pro-
spectively. These results confirmed the susceptibility of
the HRP-2 RDT brands to prozone: prozone affected
all four brands in proportions ranging from 20.6% to
85.0%. Although no negative test results were obtained,
faint test lines were observed in proportions up to
17.5%. In addition, there was a clear difference
between the two lot numbers of the Malaria Pan/Pv/
Pf Rapid Device: for 43 samples assessed by both lots,
prozone was observed in 5 (11.6%) versus 22 (51.2%)
samples respectively (p < 0.0005).
Discussion
In 2009, an estimated 225 million cases of malaria
occurred with 781.000 deaths, mostly due to P. falci-
parum in children in Africa [1]. WHO recommends
parasitological diagnostic testing before treatment.
When microscopy is not available, RDTs are the alterna-
tive. RDTs have been demonstrated to perform equally
well or even better than microscopy in field settings
[20-23] and are currently deployed at all levels of health
facilities [1].
Some limitations are however to be mentioned. The
wet season of 2009-2010 in Mozambique was character-
ized by irregular rainfall and long dry spells. Due to this
low rainfall (30% below expected value in November
2009 up to 60% in March 2010 [24]) and the impact of
local control measures in the months preceding the
study, there was less malaria than expected and the ori-
ginally planned 5% parasite density threshold (defined
by WHO as hyperparasitaemia [13]) was replaced by
4%, also used in other studies [14,15]. Although samples
below this 4% threshold were included, prozone was not
assessed below this threshold, precluding systematic
study of possible clinical or laboratory predictors of pro-
zone. Further, due to non-availability of trained staff
around the clock, it was not always possible to record
all clinical data and to work-up all samples in the
laboratory. Likewise, for logistic reasons, two RDTs were
assessed with blood samples stored at -20°C and not on
fresh samples. However, it should be noted that the
HRP-2 antigen is very stable and resistant to harsh con-
ditions [25]. For three RDTs, storage temperatures
slightly exceeded those recommended by the manufac-
turers. Finally only a minority of undiluted prozone
positive samples showed no visible test line, whereas the
remaining samples showed faint or weak test lines.
However, disregarding faint or even weak test lines as
negative is a common error among end-users in field
settings [26-28].
There are only few original studies reporting on pro-
zone in malaria RDTs [9,29]. Prozone may however
explain for the rare but consistent reports of false nega-
tive HRP-2 based RDT results in samples with high
parasite density: for instance, in a recent study of two
RDTs in Sierra Leone, two false-negative samples were
observed with the HRP-2 RDT but not with the Pf-
pLDH RDT. The parasite densities of both samples were
288,000/μl and 580.000/μl, corresponding to 5.7% and
11.6% parasite density respectively [30]. Interestingly,
the HRP-2 test used in this study was Paracheck-Pf and
the two samples accounted for 1.1% of all malaria posi-
tive samples which is in line with the present findings.
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intervals (CI) within brackets
Category Number % of patients suspected
of malaria
%o fP. falciparum positive
patients
% of samples with high
parasitaemia
Patients suspected of malaria
(1 sample per patient included)
7,543 100
Samples positive for P. falciparum 873 11.6
(10.86-12.32)
100
Samples scored as 4+ or 5 + (MoH semi-
quantitative scale)
410 5.4
(4.93-5.97)
47.0
(43.61-50.34)
Samples with a high parasitaemia (parasite
density ≥ 4%)
92 1.2
(0.98-14.9)
10,5
(8,58-12,77)
100
Number of samples available for prozone
testing
76 - - -
Negative, faint or weak HRP-2 test lines * 29 0.5
†
(0.32-0.64)
4.0
†
(2.81-5.53)
38.0
†
(28.12-48.76)
Negative or faint HRP-2 test lines * 8 0.1
†
(0.06-0.24)
1.2
†
(0.55-2.10)
10.9
†
(5.34-19.08)
Negative HRP-2 test lines * 3 0.05
†
(0.01-0.14)
0.5
†
(0.12-1.17)
4.4
†
(1.20-10.76)
* Line intensity for undiluted samples
† Proportions calculated according to Table 2, corrected for the number of samples that were not available for prozone testing (n = 16).
Table 5 Characteristics of P. falciparum samples that were prozone positive or negative for Paracheck-Pf
Samples with high parasitaemia (parasite density ≥ 4%)
Prozone positive Prozone negative Total p = *
n = 29 n = 47 n = 76
Demographic and clinical data (expressed as % of total)
Patients (n= 76) Children < 5 years (n = 53) 82.8 61.7 69.8 NS
Children ≥ 5 years (n = 14) 10.3 23.4 18.4 NS
Adults (> 14 years) (n = 9) 6.9 14.9 11.8
Gender ratio (n = 74) Male/female 40.7 57.4 51.4 NS
Presenting symptoms Fever (n = 64) 96.3 97.3 96.9 NS
Cough (n = 59) 50.0 11.4 27.1 0.002
Vomiting (n = 60) 28.0 45.7 38.3 NS
Diarrhoea (n = 60) 28.0 45.7 30.0 NS
Clinical signs of severity At least one (n = 60) 64.0 48.6 55.0 NS
Laboratory sign of severity Haemoglobin < 5 g/dl (n = 76) 20.7 6.4 11.8 NS
Signs of severity At least one clinical or laboratory (n = 61) 69.2 54.3 60.7 NS
Laboratory values (expressed as median and 95% CI)
Parasite density in % (n = 76) Median 8.0 6.9 6.9 NS
Range 4.0-28.7 4.2-22.3 4.0-28.7
Hemoglobin level (g/dl) (n = 76) Median 7.2 9.0 8.3 0.0074
Range 2.9-12.5 2.5-13.3 2.5-13.3
RBC count (× 10
9/l) (n = 76) Median 3.1 3.8 3.4 0.0131
Range 1.1-5.3 0.9-5.3 0.9-5.3
Platelet count (× 10
6/l) (n = 76) Median 74 90 86 NS
Range 12-488 13-390 12-390
WBC count (× 10
6/l) (n = 76) Median 10.4 10.1 10.2 NS
Range 4.4-19.9 3.2-27.6 3.2-27.6
* NS = not significant
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HRP-2 RDT brands have been reported from endemic
as well as non-endemic settings [31-33].
In line with previous findings, the present study
demonstrated prozone in HRP-2 but not in Pf-pLDH
based RDTs frequently used in field settings [9]. Com-
pared to HRP-2 based RDTs, pLDH based RDTs are
ascribed lower sensitivity and lower heat-stability
[23,34,35], but according to a recent field study and
the second WHO/FIND RDT evaluation round, Pf-
pLDH RDTs may perform equally well as HRP-2 RDTs
[17,36]. The observation of lot-to-lot variations in one
HRP-2 RDT brand illustrates that small differences in
composition may influence the vulnerability to pro-
z o n e .I nt h a tw a y ,i ts h o u l db en o t e dt h a tt h ep r e s e n t
data only reflect those of the examined lot numbers
and may therefore not be extrapolated to all RDT
brands. Although not assessed in the present study,
several factors in the design of the individual RDT
brands may explain for their different vulnerabilities to
the prozone effect. As antigen-antibody interactions
are time-related, factors influencing the speed of
migration may be involved, such as the pore size of
t h en i t r o c e l l u l o s em e m b r a n ea n dt h ev i s c o s i t ya n d
volume of the buffer. In addition, the structure of the
antibodies, the affinity and the avidity of the antigen-
antibody binding may be of influence. With regard to
end-user practice, application of a high blood volume
may increase the risk of prozone, as demonstrated pre-
viously [9].
From the present results, it is clear that prozone
occurred dispersedly among samples with high parasi-
taemia. Prozone with non-visible test lines occurred
exclusively in samples with parasite densities above 8%
and the frequency and intensity of prozone decreased
below the 4% threshold. However, the association para-
site density - presence of prozone among samples with
parasite densities ≥ 4% was not straightforward. This
may be ascribed to factors such as capillary sequestra-
tion of the parasites, variations in the antigen produc-
tion during the cycle and strain differences [4,37].
Prozone remains a rare phenomenon and although the
present study was not designed to trace risk factors of
prozone, this study suggests that, apart from hemoglo-
bin level, there are no clear indicators for prozone. This
relation can be explained by the high concentration of
Table 6 Number of HRP-2 RDT brands affected by prozone in relation to the parasite density and HRP-2 test line
intensity for undiluted samples (negative, faint and weak)
Parasite
density %
Number of samples
assessed
Prozone for at
least 1RDT
Prozone for at
least 2 RDTs
Prozone for at
least 3 RDTs
Prozone for at
least 4 RDTs
Prozone for at
least 5 RDTs
Weak Faint or
no line
Weak Faint or
no line
Weak Faint or
no line
Weak Faint or
no line
Weak Faint or
no line
1 to 3.9 45 10 3 * 8 - 5 - 2 - - -
4 to 4.9 18 4 4
† 807-2---
5 to 9.9 39 13 8
‡ 11 2
£ 8-4-1-
≥ 10 19 6 4
$ 81
+ 8-3-2-
* Parasite densities of 2.2, 2.9 and 3.4%
† Parasite densities of 4.1, 4.2, 4.3 and 4.7%
‡ Parasite densities of 8.0, 8.0, 8.3, 8.3, 8.4, 8.6, 8.9 and 9.3%
£ Parasite densities of 8.0 and 8.3%
$ Parasite densities of 10.6, 11.0, 11.5 and 28.7%
+ Parasite densities of 28.7%
Table 7 Number of prozone positive samples for additional HRP-2 RDT brands that were assessed with samples
positive for prozone with at least one of the RDTs from Table 3
Brands/Manufacturers P. falciparum antigen
target
Number of samples
tested
Total number of samples with
prozone (%)
HRP-2 or Pf-pLDH line
intensity for undiluted
prozone positive
samples
Negative Faint Weak
Hexagon Malaria HRP-2 39 13 (33.3%) - 0 13
Malaria Total Quick HRP-2 44 22 (50.0%) - 5 17
First Response Malaria Ag
Combo
HRP-2 40 34 (85.0%) - 7 27
ICT Malaria Combo HRP-2 34 7 (20.6%) - 1 6
Malaria Pan/Pv/Pf Rapid
‡
Device
HRP-2 43 22 (51.2%) - 4 18
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Page 9 of 11HRP-2 related to the duration of the disease and/or to
the number of malaria crises in the past few weeks.
For the two most affected RDT brand (Paracheck-Pf
and ICT Malaria), prozone with negative or faint HRP-
2 test lines (the most dangerous situation) occurred in
at least 1.2% of malaria-positive samples and 10.9% of
samples with high parasitaemia. At such frequencies, the
diagnostic accuracy may be affected and the impact on
predictive values will depend on the malaria-attributable
fraction of fevers and the proportion of high parasite
densities: both factors are related to transmission inten-
sity and pre-existing immunity of the affected popula-
tion [38]. For Africa, the P. falciparum prevalence rate
in children aged two to ten years is actually estimated at
17% [39]. For the distribution of parasite densities, pub-
lished data are scarce. Two recent studies conducted in
children in areas of perennial transmission in Gabon
and Sierra Leone reported median parasite densities of
13,860/μl (1,400 - 71,452) and 264,000/μl (1 - 2,136,000)
[22,30]. When extrapolating for Mozambique, based on
the 4,310,086 suspected malaria cases reported in 2009
[1], a 17% malaria attributable fraction [39] and a 10%
proportion of high parasitaemia, the annual numbers of
negative or faint test lines were calculated as 7,694 (CI:
3,883-13,922) and 9,643 (CI: 4,543-15,387) with Para-
check-Pf and ICT Malaria (tested with the presently
evaluated lots) respectively.
The risk related to false-negative RDT results due to
low parasite densities is mitigated by diagnostic algo-
rithms recommending to repeat testing after an unex-
pected negative RDT result [40-42]. However, such
policy will not timely correct for false-negative results
due to the prozone, as hyperparasitaemia represents a
life-threatening situation. In addition, there is a ten-
dency to roll out RDTs to poorly resourced peripheral
health care facilities where there are no further labora-
tory facilities to perform sample dilution or microscopy
in order to correct for prozone [1,20]. Possible other
measures to address prozone are training of the end-
user to understand the problem and to assure interpre-
tation of faint test lines as positive test results. Concern-
ing RDT quality control at the level of national
reference laboratories and the FIND/WHO lot testing
programme, samples with hyperparasitaemia could be
included but in view of the low prozone frequency and
its scattered distribution among samples with hyperpara-
sitaemia, it is difficult to assess prozone on a pre-release
basis. Post-marketing follow-up including incident
reporting could provide further clues. Finally, depending
on the distribution of parasite densities in a given popu-
lation, susceptibility to prozone should be added as a
major argument in the strategic choice between Pf-
pLDH and HRP-2 RDTs.
In conclusion, prozone is a rare event but it occurs
among widely used HRP-2 RDTs at frequencies that
may diminish diagnostic accuracy of the affected RDTs.
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